RT Journal Article
SR Electronic
T1 Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.06.22270359
DO 10.1101/2022.02.06.22270359
A1 Davis, Samantha K
A1 Selva, Kevin John
A1 Lopez, Ester
A1 Haycroft, Ebene R
A1 Lee, Wen Shi
A1 Wheatley, Adam K
A1 Juno, Jennifer A
A1 Adair, Amy
A1 Pymm, Phillip
A1 Redmond, Samuel J
A1 Gherardin, Nicholas A
A1 Godfrey, Dale I
A1 Tham, Wai-Hong
A1 Kent, Stephen J
A1 Chung, Amy W
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.06.22270359.abstract
AB Following infection with SARS-CoV-2, virus-specific antibodies are generated which can both neutralise virions and clear infection via Fc effector functions. The importance of IgG antibodies for protection and control of SARS-CoV-2 has been extensively reported. In comparison, other antibody isotypes including IgA have been poorly characterized. Here we characterized plasma IgA from 41 early convalescent COVID-19 subjects for neutralisation and Fc effector functions. We find that convalescent plasma IgA from >60% of the cohort have the capacity to inhibit the interaction between wild-type RBD and ACE2. Furthermore, a third of the cohort induced stronger IgA-mediated inhibition of RBD binding to ACE2 than IgG, when tested at equivalent concentrations. Plasma IgA and IgG from the cohort, broadly recognize similar RBD epitopes and showed similar ability to inhibit ACE2 from binding 22 of 23 different prevalent RBD proteins with single amino acid mutations. Plasma IgA was largely incapable of mediating antibody-dependent phagocytosis in comparison to plasma IgG. Overall, convalescent plasma IgA contributes to neutralisation towards wild-type RBD and various RBD single mutants in most subjects, although this response is heterogeneous and less potent than IgG.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Medical Research Future Fund (MRFF) (W.H.T., D.I.G., A.W.C., S.J.K., A.K.W. and J.A.J), Emergent Ventures Fast Grant (A.W.C.) and the Paul Ramsay Foundation (D.I.G., S.J.K., A.K.W and A.W.C). A.K.W., J.A.J, D.I.G., W.-H.T., S.J.K., and A.W.C are supported by NHMRC fellowships. WH.T. is a Howard Hughes Medical Institute Wellcome Trust International Research Scholar (208693/Z/17/Z). N.A.G. is supported by an ARC DECRA fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the University of Melbourne Human Research Ethics Committee (#2056689) and all associated procedures were carried out in accordance with the approved guidelines.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors